Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NN1952 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Trial part 1 | EXPERIMENTAL | - |
| Trial part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NN1952 | DRUG | Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation. |
| insulin aspart | DRUG | As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels. |
| placebo | DRUG | Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels. |
Inclusion Criteria: * FOR TRIAL PART 1, THE FOLLOWING APPLIES: * Gender: male * Age: 18-55 years * BMI (body mass index): 18-28 kg/m2 * Study participants considered to be healthy * FOR TRIAL PART 2, THE FOLLOWING APPLIES: * Gender: male or female of no childbearing potential * Age: 18-65 years * T...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NN1952 is an investigational small molecule being developed by Novo Nordisk for the treatment of diabetes, including type 1 and type 2 diabetes. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
NN1952 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The drug is in Phase 1 clinical development for the treatment of diabetes.
NN1952 is in Phase 1 clinical development. It has completed one Phase 1 trial, and the drug remains investigational, meaning it has not been approved for commercial use.
NN1952 has been studied in a completed Phase 1 trial with the identifier NCT01028404. This trial investigated the drug in healthy subjects and in subjects with type 1 and type 2 diabetes, enrolling 84 participants in Germany.
NN1952 is a distinct investigational small molecule developed by Novo Nordisk. It is being studied specifically for diabetes, but it is not the same as other marketed diabetes medications, as it is still in early clinical development.